Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses

Journal of Infectious Diseases

Volumn 201, Issue 7, 2010, Pages 1024-1030

  Weinberg, Adriana ^a,b   Lazar, Ann A ^c,g   Zerbe, Gary O ^c   Hayward, Anthony R ^a,h   Chan, Ivan S F ^d   Vessey, Rupert ^d   Silber, Jeffrey L ^d   MacGregor, Rob R ^e   Chan, Kenny ^c   Gershon, Anne A ^f   Levin, Myron J ^a,b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; ADULTHOOD; AGED; AGING; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKENPOX; CHILD; CHILDHOOD; CONTROLLED STUDY; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; INFANT; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; PRESCHOOL CHILD; PRIMARY INFECTION; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; VARICELLA ZOSTER VIRUS; WILD TYPE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; HERPESVIRUS 3, HUMAN; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INFANT; LOGISTIC MODELS; LONGITUDINAL STUDIES; MIDDLE AGED;

EID: 77749308315     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651199     Document Type: Article

References (35)

1. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981; 32:24-27. (Pubitemid 11156896)
2. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166:1153-1156.
3. Buda K, Tubergen DG, Levin MJ. The frequency and consequences of varicella exposure and varicella infection in children receiving maintenance therapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1996;18:106-112. (Pubitemid 126424974)
4. Furth SL, Sullivan EK, Neu AM, Tejani A, Fivush BA. Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997;1:37-42. (Pubitemid 127684806)
5. Gershon AA, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 1997;176:1496-1500.
6. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIVinfected children with varicella vaccine. J Pediatr 2001;139:305-310. (Pubitemid 32721722)
7. Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006;194:247-255.
8. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-835.
9. Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006; 6:565-568. (Pubitemid 43382144)
10. Hayward AR, Zerbe GO, Levin MJ. Clinical application of responder cell frequency estimates with four years of follow up. J Immunol Methods 1994;170:27-36. (Pubitemid 124014514)
11. Henry C, Marbrook J, Vann DC, Kodlin DC, Wojsy C. Limiting dilution analysis. In: Mishell BB, Shigii SM, eds. Selected methods in cell mediated immunity. San Francisco: Freeman Press, 1980:138-152.
12. Zaia JA, Leary PL, Levin MJ. Specificity of the blastogenic response of human mononuclear cells to herpesvirus antigens. Infect Immun 1978; 20:646-651. (Pubitemid 8351999)
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310. (Pubitemid 16134762)
14. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
15. Hughes JP. Mixed effects models with censored data with application to HIV RNA levels. Biometrics 1999;55:625-629.
16. Thiébaut R, Jacqumin-Gadda H, Leport C, et al. Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures. J Biopharm Stat 2003; 13:271-282.
17. Weinberg A, Wiznia AA, LaFleur BJ, Shah S, Levin MJ. Varicella-zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2004; 190:267-270.
18. Gershon A, Levin MJ, Weinberg A, et al. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis 2009; 28(7):653-655.
19. Weinberg A, Levin MJ, MacGregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Human Vaccines (in press).
20. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982; 142:291-293.
21. Miller AE. Selective decline in cellular immune response to varicellazoster in the elderly. Neurology 1980; 30:582-587.
22. Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 1983; 148: 200-205.
23. Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH. Meier P. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 1996;173:450-453. (Pubitemid 26042448)
24. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20:2500-2507.
25. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007; 356:1121-1129.
26. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360:678-682.
27. Civen R, Chaves SS, Jumaan A, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 2009; 28(11): 954-959.
28. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-2284.
29. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068-1077.
30. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23:132-137. (Pubitemid 38222785)
31. Michalik DE, Steinberg SP, Larussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 2008; 197:944-949. (Pubitemid 351590021)
32. Shu L, Chan ISF, Matthews H, Heyse JF. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002; 21:337-342. (Pubitemid 34326873)
33. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics 2007;120:221-231.
34. Levin MJ, Anderson JP, Seage GR 3rd, Williams PL. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr 2009;50:182-191.
35. Vanhems P, Voisin L, Gayet-Ageron A, et al. The incidence of herpes zoster is less likely than other opportunistic infections to be reduced by highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38: 111-113. (Pubitemid 40094129)